TN2015000112A1 - Pyrrolotriazinone derivatives as pi3k inhibitors - Google Patents

Pyrrolotriazinone derivatives as pi3k inhibitors

Info

Publication number: TN2015000112A1
Authority: TN; Tunisia
Prior art keywords: pi3k inhibitors; pyrrolotriazinone derivatives; pyrrolotriazinone; derivatives; inhibitors
Prior art date: 2012-10-16

Application number

TNP2015000112A

Other languages

English (en)

Inventor

Sola Montserrat Erra

Riera Marta Carrascal

Moll Joan Taltavull

Javaloyes Juan Francisco Caturla

Anchuela Francisco Javier Bernal

Santacana Lluis Miquel Pages

Cepeda Marta Mir

Coll Gaspar Casals

Olasagarre Maria Begoña Hernandez

Original Assignee

Almirall Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-16

Filing date

2015-03-24

Publication date

2016-06-29

2015-03-24 Application filed by Almirall Sa filed Critical Almirall Sa

2016-06-29 Publication of TN2015000112A1 publication Critical patent/TN2015000112A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Dermatology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Oncology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TNP2015000112A 2012-10-16 2015-03-24 Pyrrolotriazinone derivatives as pi3k inhibitors TN2015000112A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12382399		2012-10-16
PCT/EP2013/071551 WO2014060432A1 (fr)	2012-10-16	2013-10-15	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k

Publications (1)

Publication Number	Publication Date
TN2015000112A1 true TN2015000112A1 (en)	2016-06-29

Family

ID=47049114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000112A TN2015000112A1 (en)	2012-10-16	2015-03-24	Pyrrolotriazinone derivatives as pi3k inhibitors

Country Status (29)

Country	Link
US (1)	US9388189B2 (fr)
EP (1)	EP2909207A1 (fr)
JP (1)	JP2015533181A (fr)
KR (1)	KR20150068953A (fr)
CN (1)	CN104854108A (fr)
AP (1)	AP2015008328A0 (fr)
AR (1)	AR093036A1 (fr)
AU (1)	AU2013333938A1 (fr)
BR (1)	BR112015007231A2 (fr)
CA (1)	CA2883426A1 (fr)
CL (1)	CL2015000956A1 (fr)
CR (1)	CR20150175A (fr)
DO (1)	DOP2015000077A (fr)
EA (1)	EA027277B1 (fr)
GE (1)	GEP201706623B (fr)
GT (1)	GT201500094A (fr)
HK (1)	HK1211027A1 (fr)
IL (1)	IL237475A0 (fr)
MD (1)	MD20150048A2 (fr)
MX (1)	MX2015004327A (fr)
NI (1)	NI201500054A (fr)
PE (1)	PE20150637A1 (fr)
PH (1)	PH12015500813A1 (fr)
SG (1)	SG11201502032VA (fr)
TN (1)	TN2015000112A1 (fr)
TW (1)	TW201429975A (fr)
UY (1)	UY35086A (fr)
WO (1)	WO2014060432A1 (fr)
ZA (1)	ZA201501220B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014015523A1 (fr) *	2012-07-27	2014-01-30	Hutchison Medipharma Limited	Nouveaux composés hétéroaryliques et hétérocycliques et compositions et procédés s'y rapportant
WO2014184069A1 (fr) *	2013-05-14	2014-11-20	Nerviano Medical Sciences S.R.L.	Dérivés de 6-amino-7-désaza-purine, procédé pour les préparer et leur utilisation comme inhibiteurs de kinases
KR20160058889A (ko)	2013-09-22	2016-05-25	칼리토르 사이언시즈, 엘엘씨	치환된 아미노피리미딘 화합물 및 이용 방법
EA201692557A1 (ru)	2014-07-04	2017-05-31	Люпин Лимитед	Хинолизиноновые производные в качестве ингибиторов pi3k
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016202800A1 (fr)	2015-06-16	2016-12-22	Almirall, S.A.	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k
CN106467545B (zh) *	2015-08-20	2018-10-16	北大方正集团有限公司	一种噻吩并嘧啶化合物
WO2017076990A1 (fr)	2015-11-05	2017-05-11	Almirall, S.A.	Sels d'addition de n-[4-(4-{[(1s)-1-(5-méthyl-4-oxo-3-phényl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)éthyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
EP3371221A2 (fr)	2015-11-07	2018-09-12	MultiVir Inc.	Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer
PT3377495T (pt)	2015-11-16	2022-05-06	Topadur Pharma Ag	Derivados de 2-fenil-3,4-di-hidropirrolo[2,1- f][1,2,4]triazinona como inibidores de fosfodiesterase e suas utilizações
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017214269A1 (fr)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
SI3472165T1 (sl) *	2016-06-21	2024-02-29	Nerviano Medical Sciences S.R.L.,	N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinaz
JP2019530650A (ja)	2016-08-24	2019-10-24	アークルインコーポレイテッド	アミノ−ピロロピリミジノン化合物およびその使用方法
EP3551226A1 (fr)	2016-12-12	2019-10-16	MultiVir Inc.	Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses
JP7450541B2 (ja)	2018-01-20	2024-03-15	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	置換アミノピリミジン化合物及び使用方法
EP3768698B1 (fr)	2018-03-19	2025-02-12	MultiVir Inc.	Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer
WO2021113644A1 (fr)	2019-12-05	2021-06-10	Multivir Inc.	Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
EP4175949A4 (fr) *	2020-07-03	2024-02-28	Nanjing Immunophage Biotech Co., Ltd.	Méthodes et compositions pour cibler des treg au moyen d'inhibiteurs de ccr8

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA02010618A (es)	2000-04-25	2004-05-05	Icos Corp	Inhibidores de fosfatidilinositol 3-quinasa delta.
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
US6752411B2 (en)	2002-06-24	2004-06-22	Norco Industries, Inc.	Multi-stage torsion axle
TW200400816A (en)	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
WO2004096234A2 (fr)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Analogues de phosphonate inhibiteurs de kinase
WO2005016348A1 (fr)	2003-08-14	2005-02-24	Icos Corporation	Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
EP1761540B1 (fr) *	2004-05-13	2016-09-28	Icos Corporation	Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
DK200400182U4 (da)	2004-06-23	2005-10-14	Alfa Laval Tank Equipment As	Drivenhed især til brug i forbindelse med tankrenseudstyr
GB0417709D0 (en)	2004-08-09	2004-09-08	Glaxo Group Ltd	Compounds
EP2351745A1 (fr)	2005-08-26	2011-08-03	Merck Serono S.A.	Dérivés de pyrazine et leurs utilisations en tant qu'inhibiteurs de PI3K
EP1931642A4 (fr)	2005-09-15	2011-06-01	Orchid Res Lab Ltd	Nouveaux pyrimidine carboxamides
US7525866B2 (en)	2006-04-19	2009-04-28	Freescale Semiconductor, Inc.	Memory circuit
FI20065449A0 (fi)	2006-06-29	2006-06-29	Nokia Corp	Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline
TW200840581A (en)	2007-02-28	2008-10-16	Astrazeneca Ab	Novel pyrimidine derivatives
UY31137A1 (es)	2007-06-14	2009-01-05	Smithkline Beecham Corp	Derivados de quinazolina como inhibidores de la pi3 quinasa
ITRN20070034A1 (it)	2007-06-27	2008-12-28	Sica Spa	Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza.
TWI441601B (zh)	2007-06-28	2014-06-21	Philip Morris Products Sa	具有高白堊含量之圖案化包裝紙
CN101821238A (zh)	2007-07-26	2010-09-01	科门蒂斯公司	抑制β-分泌酶(BETA-SECRETASE)活性的间苯二酰胺衍生物
EP2300437B1 (fr)	2008-06-05	2013-11-20	Glaxo Group Limited	Dérivés de benzpyrazole en tant qu'inhibiteurs de p13 kinases
EP2303890A4 (fr)	2008-06-19	2012-04-11	Progenics Pharm Inc	Inhibiteurs de phosphatidylinositol 3 kinase
JP2012521994A (ja) *	2009-03-24	2012-09-20	ギリアードカリストガエルエルシー	２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
KR101818895B1 (ko)	2009-07-02	2018-01-15	메르츠 파마 게엠베하 운트 코. 카가아	생물학적 활성이 감소된 신경독
WO2011058109A1 (fr) *	2009-11-12	2011-05-19	Ucb Pharma S.A.	Dérivés de pyrrole et d'imidazole bicycliques condensés en tant qu'inhibiteurs de kinase
WO2011119704A1 (fr)	2010-03-23	2011-09-29	Glaxosmithkline Llc	Antagonistes de trpv4
US8604032B2 (en) *	2010-05-21	2013-12-10	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
EP2394998A1 (fr)	2010-05-31	2011-12-14	Almirall, S.A.	Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
WO2012000202A1 (fr)	2010-07-02	2012-01-05	Tsai Wen-Kai	Dispositif d'envoi de personnel de service et procédé d'envoi de personnel utilisant ledit dispositif
JP2013532688A (ja)	2010-07-26	2013-08-19	ブリストル−マイヤーズスクイブカンパニー	Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物
WO2012013727A1 (fr)	2010-07-29	2012-02-02	Oryzon Genomics S.A.	Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
WO2012145666A1 (fr)	2011-04-21	2012-10-26	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Vaccins de peptide et conjugué pour infections fongiques
EP2518070A1 (fr) *	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
CN102229416B (zh)	2011-06-29	2013-06-05	三一汽车起重机械有限公司	一种起重机闭式回转液压系统及起重机
BR112014005554A2 (pt)	2011-09-12	2017-03-21	Merck Patent Gmbh	aminas de imidazol como moduladores de atividade de quinase
WO2014015523A1 (fr)	2012-07-27	2014-01-30	Hutchison Medipharma Limited	Nouveaux composés hétéroaryliques et hétérocycliques et compositions et procédés s'y rapportant

2013
- 2013-10-15 CA CA2883426A patent/CA2883426A1/fr not_active Abandoned
- 2013-10-15 WO PCT/EP2013/071551 patent/WO2014060432A1/fr not_active Ceased
- 2013-10-15 MX MX2015004327A patent/MX2015004327A/es unknown
- 2013-10-15 JP JP2015537230A patent/JP2015533181A/ja not_active Withdrawn
- 2013-10-15 AP AP2015008328A patent/AP2015008328A0/xx unknown
- 2013-10-15 KR KR1020157009063A patent/KR20150068953A/ko not_active Withdrawn
- 2013-10-15 US US14/435,851 patent/US9388189B2/en not_active Expired - Fee Related
- 2013-10-15 PE PE2015000410A patent/PE20150637A1/es not_active Application Discontinuation
- 2013-10-15 AU AU2013333938A patent/AU2013333938A1/en not_active Abandoned
- 2013-10-15 SG SG11201502032VA patent/SG11201502032VA/en unknown
- 2013-10-15 CN CN201380065926.2A patent/CN104854108A/zh active Pending
- 2013-10-15 BR BR112015007231A patent/BR112015007231A2/pt not_active IP Right Cessation
- 2013-10-15 EP EP13779788.2A patent/EP2909207A1/fr not_active Withdrawn
- 2013-10-15 MD MDA20150048A patent/MD20150048A2/ro not_active Application Discontinuation
- 2013-10-15 EA EA201500426A patent/EA027277B1/ru not_active IP Right Cessation
- 2013-10-15 HK HK15111815.3A patent/HK1211027A1/xx unknown
- 2013-10-15 GE GEAP201313828A patent/GEP201706623B/en unknown
- 2013-10-16 AR ARP130103757A patent/AR093036A1/es unknown
- 2013-10-16 TW TW102137293A patent/TW201429975A/zh unknown
- 2013-10-16 UY UY0001035086A patent/UY35086A/es not_active Application Discontinuation
2015
- 2015-02-23 ZA ZA2015/01220A patent/ZA201501220B/en unknown
- 2015-02-26 IL IL237475A patent/IL237475A0/en unknown
- 2015-03-24 TN TNP2015000112A patent/TN2015000112A1/fr unknown
- 2015-03-30 CR CR20150175A patent/CR20150175A/es unknown
- 2015-03-30 DO DO2015000077A patent/DOP2015000077A/es unknown
- 2015-04-13 PH PH12015500813A patent/PH12015500813A1/en unknown
- 2015-04-15 CL CL2015000956A patent/CL2015000956A1/es unknown
- 2015-04-16 GT GT201500094A patent/GT201500094A/es unknown
- 2015-04-16 NI NI201500054AA patent/NI201500054A/es unknown

Also Published As

Publication number	Publication date
EA027277B1 (ru)	2017-07-31
PE20150637A1 (es)	2015-05-08
SG11201502032VA (en)	2015-05-28
CN104854108A (zh)	2015-08-19
KR20150068953A (ko)	2015-06-22
US20150291595A1 (en)	2015-10-15
MX2015004327A (es)	2015-06-10
CR20150175A (es)	2015-05-11
WO2014060432A1 (fr)	2014-04-24
AU2013333938A1 (en)	2015-04-09
EA201500426A1 (ru)	2015-10-30
HK1211027A1 (en)	2016-05-13
GT201500094A (es)	2017-08-01
EP2909207A1 (fr)	2015-08-26
US9388189B2 (en)	2016-07-12
JP2015533181A (ja)	2015-11-19
PH12015500813B1 (en)	2015-06-08
PH12015500813A1 (en)	2015-06-08
AP2015008328A0 (en)	2015-03-31
UY35086A (es)	2014-05-30
CA2883426A1 (fr)	2014-04-24
AR093036A1 (es)	2015-05-13
CL2015000956A1 (es)	2015-06-19
GEP201706623B (en)	2017-02-10
TW201429975A (zh)	2014-08-01
DOP2015000077A (es)	2015-04-30
MD20150048A2 (ro)	2015-10-31
NI201500054A (es)	2016-02-01
IL237475A0 (en)	2015-04-30
BR112015007231A2 (pt)	2017-07-04
ZA201501220B (en)	2017-04-26

Publication	Publication Date	Title
MX336214B (es)	2016-01-12	Derivados de pirrolotriazinona como inhibidores de pi3k.
PH12015500813A1 (en)	2015-06-08	Pyrrolotriazinone derivatives as pi3k inhibitors
PH12012502334A1 (en)	2013-02-11	Heteroaryl imidazolone derivatives as jak inhibitors
PH12014500103A1 (en)	2019-03-22	Pyridin-2(1h)-one derivatives as jak inhibitors
PH12012501164A1 (en)	2017-08-23	Imidazopyridine derivatives as jak inhibitors
NZ708870A (en)	2016-09-30	Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
MY177344A (en)	2020-09-13	Compounds and their methods of use
PH12014501542A1 (en)	2014-09-22	Substituted pyrrolidine -2- carboxamides
MX386473B (es)	2025-03-18	Formas solidas de un inhibidor de cdk4/6 selectivo
JO3193B1 (ar)	2018-03-08	مشتقات ثينوبيريميدين جديدة وعملية لتحضيرها والتركيبات الدوائية التي تحتوي عليها
TR201816379T4 (tr)	2018-11-21	DNA-PK inhibitörleri.
MD20140002A2 (ro)	2014-06-30	Indazoli
MX352927B (es)	2017-12-14	Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
MY181602A (en)	2020-12-29	Isochromene derivatives as phosphoinositide 3-kinases inhibitors
IN2015DN01151A (fr)	2015-06-26
EA201590183A1 (ru)	2015-06-30	Производные азаиндола, выступающие в качестве ингибиторов pi3k
PH12015501175A1 (en)	2015-08-17	Substituted pyridopyrazines as syk inhibitors
MX2016003522A (es)	2016-12-15	Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
UY35332A (es)	2014-11-28	Derivados de pirrolotriazina como inhibidores de pi3k
UY35087A (es)	2014-05-30	Derivados de pirrolotriazinona como inhibidores de pi3k
GEP201706675B (en)	2017-05-25	Imidazo-triazine derivatives as pde10 inhibitors
IN2015DN00950A (fr)	2015-06-12
IN2014DN10658A (fr)	2015-08-28
ECSP15015088A (es)	2015-12-31	Derivados de pirrolotriazinona como inhibidores de pi3k